Loading candles…
Beta Drugs Ltd is an India-based pharmaceutical company specializing in the development, manufacturing, and marketing of anti-cancer drugs. Its operations encompass the production of Active Pharmaceutical Ingredients (APIs) and finished dosage formulations within the oncology segment. Serving both domestic and export markets, the company holds a notable position in the Indian oncology market through its integrated operations. Beta Drugs Ltd operates primarily in the pharmaceutical and oncology industries. No information on incorporation year, founders, key management, subsidiaries, listings, or notable projects is available.
This page is a live market overview for BETA DRUGS LIMITED (BETA) on the NSE. As a listed security, BETA DRUGS LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for BETA before placing trades on tick2trade.
As of the latest feed, BETA last traded at ₹2,188 on NSE, up ₹83 (3.94%) from the previous close of ₹2,105. Today's session range is ₹2,105 – ₹2,233.9, against a 52-week band of ₹990.1 – ₹2,807.9. Traded volume today stands at 29.96K shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for BETA in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether BETA is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for BETA DRUGS LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in BETA. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated BETA option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Other | To consider other business matters | 3 Sep 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 20 Jul 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 14 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 14 Feb 2026 |
| Other | To consider other business matters (a) acquisition of equity shares of a target company from certain shareholders of the target company; (b) issue certain e… | 9 Jan 2026 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.